JP2022519326A - 診断および治療目的のためのエキソソーム関連マイクロバイオームの単離および検出 - Google Patents

診断および治療目的のためのエキソソーム関連マイクロバイオームの単離および検出 Download PDF

Info

Publication number
JP2022519326A
JP2022519326A JP2021546281A JP2021546281A JP2022519326A JP 2022519326 A JP2022519326 A JP 2022519326A JP 2021546281 A JP2021546281 A JP 2021546281A JP 2021546281 A JP2021546281 A JP 2021546281A JP 2022519326 A JP2022519326 A JP 2022519326A
Authority
JP
Japan
Prior art keywords
cancer
microbial
patient
disease
exosomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021546281A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519326A5 (https=
Inventor
ラグー カルリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2022519326A publication Critical patent/JP2022519326A/ja
Publication of JP2022519326A5 publication Critical patent/JP2022519326A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021546281A 2019-02-08 2020-02-07 診断および治療目的のためのエキソソーム関連マイクロバイオームの単離および検出 Pending JP2022519326A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802994P 2019-02-08 2019-02-08
US62/802,994 2019-02-08
PCT/US2020/017224 WO2020163724A1 (en) 2019-02-08 2020-02-07 Isolation and detection of exosome-associated microbiome for diagnostic and therapeutic purposes

Publications (2)

Publication Number Publication Date
JP2022519326A true JP2022519326A (ja) 2022-03-22
JP2022519326A5 JP2022519326A5 (https=) 2023-02-15

Family

ID=71947984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546281A Pending JP2022519326A (ja) 2019-02-08 2020-02-07 診断および治療目的のためのエキソソーム関連マイクロバイオームの単離および検出

Country Status (8)

Country Link
US (1) US20220137056A1 (https=)
EP (1) EP3921325A4 (https=)
JP (1) JP2022519326A (https=)
KR (1) KR20210125532A (https=)
CN (1) CN113631725A (https=)
AU (1) AU2020218358A1 (https=)
CA (1) CA3129250A1 (https=)
WO (1) WO2020163724A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3775258A4 (en) 2018-03-28 2022-01-26 Board of Regents, The University of Texas System IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES
WO2021158966A1 (en) 2020-02-05 2021-08-12 Board Of Regents, The University Of Texas System Diagnostic and prognostic utility of exosomes in immunotherapy
EP4373976A4 (en) * 2021-07-20 2025-06-18 Liquid Biopsy Holdco, LLC METHODS FOR DIAGNOSIS OF DISEASE USING MICROBIAL EXTRACELLULAR VESICLE (MEV) ANALYTES
CN114486829B (zh) * 2022-01-24 2023-06-27 复旦大学 一种微量外泌体捕集并计数的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015149A2 (en) * 2012-07-18 2014-01-23 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
JP2017501694A (ja) * 2013-12-04 2017-01-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析
JP2018063182A (ja) * 2016-10-13 2018-04-19 国立大学法人 新潟大学 腸内細菌の菌叢分析方法及び被検体におけるヘリコバクター・ピロリに対するアレルギーの検出方法
WO2018175422A1 (en) * 2017-03-23 2018-09-27 Quadrant Biosciences Inc. Method for diagnosing or monitoring conditions characterized by abnormal temporal variations method of normalizing epigenetic data to compensate for temporal variations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807045D0 (en) * 1998-04-01 1998-06-03 Rudi Knut Nucleic acid detection method
KR101810799B1 (ko) * 2008-02-01 2017-12-19 더 제너럴 하스피탈 코포레이션 의학적 질환 및 병태의 진단, 예후, 및 치료에 있어서 미세소포체의 용도
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
WO2011027956A2 (ko) * 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
US20130029339A1 (en) * 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
CA2846804A1 (en) * 2011-08-26 2013-03-07 Microbiota Diagnostics, Llc Methods for diagnosing and treating cardiac defects
KR101798176B1 (ko) * 2014-12-16 2017-11-15 주식회사 엠디헬스케어 세균 유래의 나노소포체를 이용한 세균성 감염질환 원인균 동정방법
KR101726488B1 (ko) * 2015-02-23 2017-04-13 이화여자대학교 산학협력단 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
US10526665B2 (en) * 2016-03-04 2020-01-07 University Of Notre Dame Du Lac Exosomal biomarkers diagnostic of tuberculosis
KR20180076308A (ko) * 2016-12-26 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 췌장암 진단방법
WO2018124618A1 (ko) * 2016-12-26 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 췌장암 진단방법
KR101940426B1 (ko) * 2016-12-28 2019-01-18 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법
WO2018124735A1 (ko) * 2016-12-28 2018-07-05 주식회사 엠디헬스케어 세균 메타게놈 분석을 통한 대장종양 진단 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014015149A2 (en) * 2012-07-18 2014-01-23 Exosome Diagnostics, Inc. Use of microvesicles in diagnosis, prognosis, and treatment of medical diseases and conditions
JP2017501694A (ja) * 2013-12-04 2017-01-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 診断および療法のためのエキソソーム中のゲノムｄｎａ、ｒｎａおよびタンパク質の分析
JP2018063182A (ja) * 2016-10-13 2018-04-19 国立大学法人 新潟大学 腸内細菌の菌叢分析方法及び被検体におけるヘリコバクター・ピロリに対するアレルギーの検出方法
WO2018175422A1 (en) * 2017-03-23 2018-09-27 Quadrant Biosciences Inc. Method for diagnosing or monitoring conditions characterized by abnormal temporal variations method of normalizing epigenetic data to compensate for temporal variations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
EXP. NEUROBIOL., vol. 26, no. 6, JPN6024002258, December 2017 (2017-12-01), pages 369 - 379, ISSN: 0005617864 *

Also Published As

Publication number Publication date
EP3921325A4 (en) 2022-11-23
CN113631725A (zh) 2021-11-09
EP3921325A1 (en) 2021-12-15
KR20210125532A (ko) 2021-10-18
AU2020218358A1 (en) 2021-08-26
US20220137056A1 (en) 2022-05-05
WO2020163724A1 (en) 2020-08-13
CA3129250A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
US20200283851A1 (en) METHODS OF DETECTING miRNA
JP2022519326A (ja) 診断および治療目的のためのエキソソーム関連マイクロバイオームの単離および検出
Ye et al. CircRNA_103765 acts as a proinflammatory factor via sponging miR-30 family in Crohn’s disease
JP6281873B2 (ja) 新規癌マーカーおよびその利用
Chen et al. Development of new techniques and clinical applications of liquid biopsy in lung cancer management
CN112359118B (zh) 长链非编码rna ac073352.1作为乳腺癌诊断标志物和治疗靶点的应用
Zhao et al. Analysis of the expression profile of serum exosomal lncRNA in breast cancer patients
Bai et al. Analysis of vaginal flora diversity and study on the role of Porphyromonas asaccharolytica in promoting IL-1β in regulating cervical cancer
Özkan et al. Human Organ Chips Reveal New Inflammatory Bowel Disease Drivers
Tataranu Liquid biopsy as a diagnostic and monitoring tool in glioblastoma
Gao et al. Meningeal blood vessel blockage enhances anti-glioblastoma immunity
CN107583052B (zh) miR-6734-5p在制备Luminal型乳腺癌诊断工具中的应用
CN118360408A (zh) C11orf52作为标志物在制备肠癌诊断及预后产品中的应用
CN113454242A (zh) 使用微小rna诊断胃癌的方法
JP6173577B1 (ja) 細胞増殖法を用いた循環腫瘍細胞の検出・分離取得方法
CN115261476A (zh) 筛选血清外泌体LncRNA HULC作为肝癌早期标记物的方法及其制备试剂盒的用途
Zhang et al. Longitudinal Monitoring of Glioblastoma Small Extracellular Vesicle Evolution Using a Nanodiagnostic to Detect Emergence of Glioma Stem Cells Driving Recurrent Disease
EP4370712A1 (en) Methods of detecting sjögren's syndrome using salivary exosomes
JP7802367B2 (ja) 膵臓がんのバイオマーカーとしてのマイクロｒｎａの使用
CN116622835B (zh) lncRNA CASC15作为肝纤维化生物标志物的应用
JP6041297B2 (ja) 犬リンパ腫の診断方法及び診断キット
CN105950705A (zh) 一组microRNAs在制备阿尔兹海默氏症诊断试剂或诊断试剂盒中的应用
US20250264386A1 (en) Methods and devices from isolation of tumor cells
Garcia Plasma-Derived Extracellular Vesicles (EVs) as a Platform for Studying Glioma Immunoregulation & Monitoring
CN107604076A (zh) 胶质瘤诊断标志物Circ6:4891713|4892379及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240423

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250203